CU20170039A7 - Método de purificación del anticuerpo humanizado 9e4 - Google Patents

Método de purificación del anticuerpo humanizado 9e4

Info

Publication number
CU20170039A7
CU20170039A7 CUP2017000039A CU20170039A CU20170039A7 CU 20170039 A7 CU20170039 A7 CU 20170039A7 CU P2017000039 A CUP2017000039 A CU P2017000039A CU 20170039 A CU20170039 A CU 20170039A CU 20170039 A7 CU20170039 A7 CU 20170039A7
Authority
CU
Cuba
Prior art keywords
solid phase
impurities
antibody
perform
respect
Prior art date
Application number
CUP2017000039A
Other languages
English (en)
Inventor
Patrick Garidel
Michael Grundman
Andreas Langer
Original Assignee
Prothena Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51355583&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU20170039(A7) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Prothena Biosciences Ltd filed Critical Prothena Biosciences Ltd
Publication of CU20170039A7 publication Critical patent/CU20170039A7/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Analytical Chemistry (AREA)
  • Inorganic Chemistry (AREA)

Abstract

Un método de purificación de un anticuerpo 9E4 humanizado caracterizado en que comprende la realización de una cromatografía en fase sólida de proteína A, en donde el anticuerpo 9E4 se une preferentemente a la fase sólida con respecto a las impurezas; la realización de la cromatografia de intercarnbio aniónico de fase sólida, en donde el anticuerpo 9E4 eluye preferentemente de la fase sólida con respecto a las impurezas; realizar una cromatografía de intercambio catiónico en fase sólida, en donde el anticuerpo 9E4 se une preferentemente a la fase sólida con respecto a las impurezas; realizar una inactivación viral y/o etapa de eliminación; realizar una etapa de filtración; y realizar una etapa de concentración y resuspensión.
CUP2017000039A 2013-07-04 2014-07-03 Método de purificación del anticuerpo humanizado 9e4 CU20170039A7 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361843011P 2013-07-04 2013-07-04
US201461979886P 2014-04-15 2014-04-15
PCT/IB2014/062806 WO2015001504A2 (en) 2013-07-04 2014-07-03 Antibody formulations and methods

Publications (1)

Publication Number Publication Date
CU20170039A7 true CU20170039A7 (es) 2017-06-05

Family

ID=51355583

Family Applications (2)

Application Number Title Priority Date Filing Date
CUP2017000039A CU20170039A7 (es) 2013-07-04 2014-07-03 Método de purificación del anticuerpo humanizado 9e4
CUP2016000001A CU20160001A7 (es) 2013-07-04 2016-01-04 Una formulación farmacéutica que comprende una versión quimérica, una versión de fragmentos no humanos o humanizados del anticuerpo 9e4

Family Applications After (1)

Application Number Title Priority Date Filing Date
CUP2016000001A CU20160001A7 (es) 2013-07-04 2016-01-04 Una formulación farmacéutica que comprende una versión quimérica, una versión de fragmentos no humanos o humanizados del anticuerpo 9e4

Country Status (17)

Country Link
US (2) US10513555B2 (es)
EP (2) EP3524264A1 (es)
JP (3) JP6404338B2 (es)
KR (1) KR20160030247A (es)
CN (1) CN105492019B (es)
AU (1) AU2014285719A1 (es)
CA (1) CA2917097C (es)
CL (1) CL2015003801A1 (es)
CU (2) CU20170039A7 (es)
ES (1) ES2704440T3 (es)
IL (1) IL243425A0 (es)
MX (1) MX2016000201A (es)
PE (1) PE20160868A1 (es)
PH (1) PH12015502788A1 (es)
RU (1) RU2016103079A (es)
SG (1) SG11201510601TA (es)
WO (1) WO2015001504A2 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2937409T3 (es) 2011-10-28 2023-03-28 Prothena Biosciences Ltd Anticuerpos humanizados que reconocen la alfa-sinucleína
IN2014DN07149A (es) 2012-01-27 2015-04-24 Neotope Biosciences Ltd
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
EP3129051A1 (en) 2014-04-08 2017-02-15 Prothena Biosciences Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
GB201512203D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
EP4470648A3 (en) 2015-08-13 2025-03-05 Amgen Inc. Charged depth filtration of antigen-binding proteins
EP3357508A4 (en) * 2015-09-28 2019-04-24 Suzhou Suncadia Biopharmaceuticals Co., Ltd. STABLE PHARMACEUTICAL ANTI-PD-1 ANTIBODY PREPARATION AND APPLICATION THEREOF IN MEDICINE
CN105127166A (zh) * 2015-09-29 2015-12-09 中国华能集团清洁能源技术研究院有限公司 行走组件及具有其的光伏组件清洁装置
SMT202100317T1 (it) * 2016-06-27 2021-07-12 Morphosys Ag Formulazioni di anticorpi anti-cd19
CA3043651A1 (en) * 2016-11-15 2018-05-24 H. Lundbeck A/S Agents, uses and methods for the treatment of synucleinopathy
BR112018016717A2 (pt) 2016-12-16 2018-12-26 H Lundbeck As agentes, usos e métodos
US10364286B2 (en) 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
EA201991720A1 (ru) 2017-02-17 2020-01-20 Бристол-Маерс Сквибб Компани Антитела к альфа-синуклеину и их применения
JP2021502955A (ja) * 2017-09-28 2021-02-04 プロセナ・バイオサイエンシズ・リミテッド シヌクレイン病の治療のための投与レジメン
GB201720970D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Antibodies
GB201720975D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Anti-alpha synuclein antibodies
JP6831861B2 (ja) 2019-01-25 2021-02-17 株式会社Ｇｒｉｎ 歯科用測定器具、測定方法、及びアタッチメント器具
CN120241997A (zh) 2019-02-18 2025-07-04 伊莱利利公司 治疗性抗体制剂
EP3786174A1 (en) * 2019-08-27 2021-03-03 Ichnos Sciences SA Methods for antibody purification
GB2587228B (en) * 2019-09-20 2021-10-27 Protein Ark Ltd Biological sample purification apparatus, use of the same, and systems comprising the same
UY39337A (es) 2020-07-23 2022-02-25 Othair Prothena Ltd Anticuerpos anti-abeta
EP4211162A4 (en) 2020-09-10 2025-04-30 Prothena Biosciences Limited TREATMENT OF PARKINSON'S DISEASE
CN114516914B (zh) * 2020-11-19 2023-04-28 东莞市朋志生物科技有限公司 抗n末端脑钠肽前体的抗体和检测n末端脑钠肽前体的试剂和试剂盒
AU2022348798A1 (en) 2021-09-16 2024-03-14 H. Lundbeck A/S Compositions and methods for treating synucleinopathies

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
IE64738B1 (en) 1990-03-20 1995-09-06 Akzo Nv Stabilized gonadotropin containing preparations
ES2206447T3 (es) 1991-06-14 2004-05-16 Genentech, Inc. Anticuerpo humanizado para heregulina.
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
DE69620877T2 (de) 1995-02-06 2002-12-12 Genetics Institute, Inc. Arzneimittelformulierungen für il-12
DE19539493A1 (de) 1995-10-24 1997-04-30 Thomae Gmbh Dr K Starker homologer Promotor aus Hamster
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
MY128897A (en) 1999-02-05 2007-02-28 Samsung Electronics Co Ltd Image texture retrieving method and apparatus thereof
AU2002248184C1 (en) 2000-12-12 2018-01-04 Board Of Regents, The University Of Texas System Molecules with extended half-lives, compositions and uses thereof
CA2491864C (en) 2001-07-12 2012-09-11 Jefferson Foote Super humanized antibodies
ES2314227T7 (es) 2002-04-09 2012-11-19 Flamel Technologies Formulacion farmaceutica oral en forma de suspension acuosa de microcapsulas que permiten la liberacion modificada de amoxilicina.
US20060024666A1 (en) 2002-05-13 2006-02-02 Shana Frederickson Humanized antibodies against the venezuelan equine encephalitis virus
US20080014194A1 (en) 2003-10-31 2008-01-17 Elan Pharmaceuticals, Inc. Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US9034337B2 (en) 2003-10-31 2015-05-19 Prothena Biosciences Limited Treatment and delay of outset of synucleinopathic and amyloidogenic disease
TW200509968A (en) 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
MXPA05005481A (es) 2002-11-29 2005-07-25 Boehringer Ingelheim Pharma Nuevos genes de la fosfotransferasa de neomicina y procedimiento para la seleccion de celulas recombinantes de produccion elevada.
EP1610820B2 (en) 2003-04-04 2013-08-21 Genentech, Inc. High concentration antibody and protein formulations
US7358331B2 (en) 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
DE10338531A1 (de) 2003-08-19 2005-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Reklonierung von Produktionszellen
WO2005047860A2 (en) 2003-11-08 2005-05-26 Elan Pharmaceuticals, Inc. Antibodies to alpha-synuclein
CA2548817A1 (en) 2003-12-04 2005-06-23 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
ES2325931T3 (es) 2004-11-10 2009-09-24 BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG Utilizacion del analisis por citometria de flujo para optimizar las estrategias de almacenamiento en bancos de celulas para celulas cho.
WO2007011907A2 (en) 2005-07-19 2007-01-25 University Of Rochester Alpha-synuclein antibodies and methods related thereto
WO2007075283A2 (en) * 2005-12-06 2007-07-05 Amgen Inc. Polishing steps used in multi-step protein purification processes
CL2007002070A1 (es) 2006-07-14 2008-02-08 Ac Immune S A Genentech Inc Anticuerpo quimerico o humanizado, o fragmentos de ellos, que se adhieren especificamente a por lo menos un epitopo en la proteina beta-amiloide; molecula de acido nucleico que lo codifica; composicion que lo comprende; su uso para tratar enfermedade
US20080124760A1 (en) 2006-07-26 2008-05-29 Barbara Enenkel Regulatory Nucleic Acid Elements
US8147833B2 (en) * 2007-02-23 2012-04-03 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
DK3067066T3 (da) 2007-02-23 2019-05-20 Prothena Biosciences Ltd Forebyggelse og behandling af synukleinopatisk og amyloidogenisk sygdom
SG178804A1 (en) 2007-02-23 2012-03-29 Schering Corp Engineered anti-il-23p19 antibodies
EP2522730A1 (en) 2007-03-02 2012-11-14 Boehringer Ingelheim Pharma GmbH & Co. KG Improvement of protein production
UA102994C2 (ru) 2007-03-22 2013-09-10 Дженентек, Инк. АНТИТЕЛО, КОТОРОЕ СПЕЦИФИЧНО СВЯЗЫВАЕТСЯ С IgE/M1' И ИНДУЦИРУЕТ АПОПТОЗ В ЭКСПРЕССИРУЮЩИХ IgE В-КЛЕТКАХ
US20100260766A1 (en) * 2007-03-22 2010-10-14 Arvind Srivastava Stable antibody formulations
EP2031064A1 (de) 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Steigerung von Proteintitern
JP5490714B2 (ja) * 2007-11-28 2014-05-14 メディミューン，エルエルシー タンパク質製剤
AU2008340429C1 (en) 2007-12-21 2016-09-08 F. Hoffmann-La Roche Ag Antibody formulation
PT2237803E (pt) 2007-12-28 2015-10-16 Prothena Biosciences Ltd Tratamento e profilaxia da amiloidose
EP3470079A1 (en) 2008-04-29 2019-04-17 BioArctic AB Antibodies and vaccines for use in therapeutic and diagnostic methods for alpha-synuclein-related disorders
WO2009141239A1 (en) * 2008-05-20 2009-11-26 F. Hoffmann-La Roche Ag A pharmaceutical formulation comprising an antibody against ox40l, uses thereof
US20120276019A1 (en) 2008-07-25 2012-11-01 Diamedica Inc. Tissue kallikrein for the treatment of parkinson's disease
KR101781228B1 (ko) 2008-12-19 2017-09-22 바이오겐 인터내셔널 뉴로사이언스 게엠베하 인간 항-알파-시누클레인 자가항체
RU2733466C2 (ru) 2009-07-28 2020-10-01 Шайр Хьюман Дженетик Терапиз Композиции и способы для лечения болезни гоше
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
EP2519537A4 (en) 2009-12-29 2013-07-10 Reddys Lab Ltd Dr CLEANING PROTEINS
EP2366714A1 (en) 2010-03-03 2011-09-21 Dr. Rentschler Holding GmbH & Co. KG Naturally occuring autoantibodies against alpha-synuclein that inhibit the aggregation and cytotoxicity of alpha-synuclein
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
JP6060073B2 (ja) 2010-04-08 2017-01-11 ジェイエヌ バイオサイエンシーズ エルエルシー Ｃｄ１２２に対する抗体
TWI526161B (zh) 2010-06-10 2016-03-21 亞培公司 包含鈣ｈｍｂ及可溶性蛋白質之實質上透明營養液
TWI629483B (zh) 2010-06-11 2018-07-11 協和醱酵麒麟有限公司 anti-TIM-3 antibody
CN103153331B (zh) 2010-07-15 2017-03-22 亚德赫伦医疗公司 靶向于钙粘着蛋白‑11的ec1结构域的人源化抗体及相关组合物和方法
MX344268B (es) * 2010-10-11 2016-12-09 Abbvie Inc * Proceso para purificacion de proteinas.
EP2673635A4 (en) 2011-02-07 2015-08-12 Neotope Biosciences Ltd IMMUNOTHERAPY THROUGH APOE
WO2012160536A1 (en) 2011-05-26 2012-11-29 Dr Reddy's Laboratories Limited Antibody purification
EP2723384B1 (en) 2011-06-22 2018-08-29 The General Hospital Corporation Treatment of proteinopathies
US20130004484A1 (en) * 2011-06-30 2013-01-03 Genentech, Inc. Anti-c-met antibody formulations
EP2771029A4 (en) * 2011-10-25 2015-07-01 Onclave Therapeutics Ltd ANTIBODY FORMULATIONS AND METHOD THEREFOR
ES2937409T3 (es) 2011-10-28 2023-03-28 Prothena Biosciences Ltd Anticuerpos humanizados que reconocen la alfa-sinucleína
HRP20230153T1 (hr) 2011-10-31 2023-03-31 F. Hoffmann-La Roche Ag Formulacije protutijela protiv il13
IN2014DN07149A (es) 2012-01-27 2015-04-24 Neotope Biosciences Ltd
US9216219B2 (en) * 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
PL2890712T3 (pl) 2012-08-29 2019-09-30 F.Hoffmann-La Roche Ag Przenośnik wahadłowy przez barierę krew-mózg
US8925815B2 (en) 2012-09-05 2015-01-06 Symbol Technologies, Inc. Checkout system for and method of preventing a customer-operated accessory reader facing a bagging area from imaging targets on products passed through a clerk-operated workstation to the bagging area
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
EP3129051A1 (en) 2014-04-08 2017-02-15 Prothena Biosciences Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
US10084674B2 (en) 2015-09-09 2018-09-25 International Business Machines Corporation Virtual desktop operation and data continuity preservation

Also Published As

Publication number Publication date
KR20160030247A (ko) 2016-03-16
EP3016677B1 (en) 2018-12-19
JP6854266B2 (ja) 2021-04-07
EP3524264A1 (en) 2019-08-14
MX2016000201A (es) 2016-05-31
SG11201510601TA (en) 2016-01-28
PE20160868A1 (es) 2016-09-24
ES2704440T3 (es) 2019-03-18
CA2917097A1 (en) 2015-01-08
WO2015001504A2 (en) 2015-01-08
US10513555B2 (en) 2019-12-24
US20150079074A1 (en) 2015-03-19
CA2917097C (en) 2022-05-03
CN105492019A (zh) 2016-04-13
CN105492019B (zh) 2020-02-11
CL2015003801A1 (es) 2016-07-15
PH12015502788A1 (en) 2016-03-21
HK1223544A1 (zh) 2017-08-04
JP2021020941A (ja) 2021-02-18
EP3016677A2 (en) 2016-05-11
JP2016534052A (ja) 2016-11-04
US20200140534A1 (en) 2020-05-07
JP6404338B2 (ja) 2018-10-10
WO2015001504A3 (en) 2015-08-06
IL243425A0 (en) 2016-03-31
JP2019011339A (ja) 2019-01-24
RU2016103079A (ru) 2017-08-07
AU2014285719A1 (en) 2016-01-21
CU20160001A7 (es) 2016-08-31

Similar Documents

Publication Publication Date Title
CU20170039A7 (es) Método de purificación del anticuerpo humanizado 9e4
CY1124921T1 (el) Μεθοδοι για την εκχυλιση και τον καθαρισμο μη μετουσιωμενων πρωτεϊνων
CY1125281T1 (el) Διαδικασια συνεχους ροης πολλαπλων σταδιων για τον καθαρμο αντισωματων
SG10201902924RA (en) Antibodies that bind ebola glycoprotein and uses thereof
MX375524B (es) Anticuerpos anti-axl.
AR108800A1 (es) Purificación de anticuerpos multiespecíficos
EA201690314A1 (ru) Анти-garp-белок и его применения
PE20170665A1 (es) Anticuerpos anti-tau humanizados
WO2015191911A3 (en) Protein enriched microvesicles and methods of making and using the same
EA202092435A2 (ru) Моноклональные антитела против bcma
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
MX2016016883A (es) Anticuerpo anti-axl.
CL2015002756A1 (es) Moléculas fc biespecíficas
ES2687282T3 (es) Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos
MX374811B (es) Anticuerpos anti-tau y métodos de uso.
EA201591806A1 (ru) Лечение и профилактика острой почечной недостаточности с применением анти-альфа-v-бета-5 антител
PE20161032A1 (es) Anticuerpos anti-tau(ps422) humanizados y metodos de utilizacion
EA201691473A1 (ru) Биспецифические анти-il-13/il-17 антитела и их применение
EA201690992A1 (ru) Антитела, специфичные к fcrn
FR3025515B1 (fr) Procede de purification d'un anticorps monoclonal
IL264375B (en) Methods of purifying fc-containing proteins
CO2017010631A2 (es) Método para purificación de proteína
SA518400237B1 (ar) SIRPa أجسم مضادة لـ جديدة وتطبيقاتها العلاجية
EA201600429A1 (ru) Способ очистки 2,5-дихлорфенола
MY181081A (en) Method for purifying antibody having low isoelectric point